Space-time clustering of recently-diagnosed tuberculosis and impact of ART scale-up: Evidence from an HIV hyper-endemic rural South African population.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 07 2019
24 07 2019
Historique:
received:
07
02
2019
accepted:
28
06
2019
entrez:
26
7
2019
pubmed:
26
7
2019
medline:
22
10
2020
Statut:
epublish
Résumé
In HIV hyperendemic sub-Saharan African communities, particularly in southern Africa, the likelihood of achieving the Sustainable Development Goal of ending the tuberculosis (TB) epidemic by 2030 is low, due to lack of cost-effective and practical interventions in population settings. We used one of Africa's largest population-based prospective cohorts from rural KwaZulu-Natal Province, South Africa, to measure the spatial variations in the prevalence of recently-diagnosed TB disease, and to quantify the impact of community coverage of antiretroviral therapy (ART) on recently-diagnosed TB disease. We collected data on TB disease episodes from a population-based sample of 41,812 adult individuals between 2009 and 2015. Spatial clusters ('hotspots') of recently-diagnosed TB were identified using a space-time scan statistic. Multilevel logistic regression models were fitted to investigate the relationship between community ART coverage and recently-diagnosed TB. Spatial clusters of recently-diagnosed TB were identified in a region characterized by a high prevalence of HIV and population movement. Every percentage increase in ART coverage was associated with a 2% decrease in the odds of recently-diagnosed TB (aOR = 0.98, 95% CI:0.97-0.99). We identified for the first time the clear occurrence of recently-diagnosed TB hotspots, and quantified potential benefit of increased community ART coverage in lowering tuberculosis, highlighting the need to prioritize the expansion of such effective population interventions targeting high-risk areas.
Identifiants
pubmed: 31341191
doi: 10.1038/s41598-019-46455-7
pii: 10.1038/s41598-019-46455-7
pmc: PMC6656755
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10724Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI124389
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD084233
Pays : United States
Références
PLoS One. 2017 Oct 13;12(10):e0181797
pubmed: 29028800
J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):104-8
pubmed: 26322671
BMC Med. 2018 Oct 18;16(1):193
pubmed: 30333043
Glob Health Action. 2014 Oct 29;7:25496
pubmed: 25377332
J Int AIDS Soc. 2017 Jul 18;20(1):21691
pubmed: 28782333
Soc Sci Med. 2016 Aug;163:144-56
pubmed: 27423295
Bull World Health Organ. 2010 Aug 1;88(8):593-600
pubmed: 20680124
PLoS One. 2013 Sep 17;8(9):e75466
pubmed: 24069418
PLoS Med. 2012;9(7):e1001270
pubmed: 22911011
Sci Rep. 2019 Jan 30;9(1):979
pubmed: 30700798
Int J Epidemiol. 2018 Apr 1;47(2):537-549
pubmed: 29300904
J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):263-9
pubmed: 21317585
Science. 2016 Aug 19;353(6301):731
pubmed: 27540141
Popul Health Metr. 2011 Aug 05;9:47
pubmed: 21819602
Public Health Action. 2016 Sep;6(3):164-168
pubmed: 27695678
J R Soc Interface. 2015 May 6;12(106):
pubmed: 25878131
Lancet Infect Dis. 2015 Sep;15(9):1066-1076
pubmed: 26112077
J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):164-174
pubmed: 28291049
AIDS Behav. 2018 Jul;22(7):2368-2379
pubmed: 29779162
Lancet. 2016 Oct 8;388(10053):1603-1658
pubmed: 27733283
S Afr Med J. 2010 Feb 03;100(3):146-7
pubmed: 20459930
Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19485-9
pubmed: 20974976
Lancet. 2013 Oct 5;382(9899):1183-94
pubmed: 23915882
S Afr Med J. 2018 Jul 25;108(8):12370
pubmed: 30182871
PLoS One. 2015 Apr 07;10(4):e0122514
pubmed: 25849558
Clin Infect Dis. 2019 Jun 18;69(1):159-166
pubmed: 30383204
Lancet Infect Dis. 2016 Feb;16(2):227-38
pubmed: 26867464
PLoS One. 2014 Jun 17;9(6):e99880
pubmed: 24937804
Science. 2013 Feb 22;339(6122):961-5
pubmed: 23430655
BMC Infect Dis. 2018 Sep 26;18(1):481
pubmed: 30257667
Int J Tuberc Lung Dis. 2018 Mar 1;22(3):287-293
pubmed: 29471906
J Int AIDS Soc. 2015 Sep 25;18:20240
pubmed: 26411694
Lancet. 2015 Dec 5;386(10010):2324-33
pubmed: 26515676
Bull World Health Organ. 2019 Jun 1;97(6):405-414
pubmed: 31210678
Am J Respir Crit Care Med. 2010 Oct 15;182(8):1080-5
pubmed: 20558626
J Health Econ. 2014 May;35:34-46
pubmed: 24595066
Science. 2013 Feb 22;339(6122):966-71
pubmed: 23430656
Int J Tuberc Lung Dis. 2017 Nov 1;21(11):1147-1154
pubmed: 29037295
Int J Epidemiol. 2009 Aug;38(4):1008-16
pubmed: 19261659
Lancet. 2012 Dec 8;380(9858):2029-43
pubmed: 23201214
Public Health Action. 2016 Dec 21;6(4):247-251
pubmed: 28123962
Trop Med Int Health. 2013 Aug;18(8):934-41
pubmed: 23731253
Arch Intern Med. 2003 May 12;163(9):1009-21
pubmed: 12742798
Lancet. 2016 Oct 8;388(10053):1459-1544
pubmed: 27733281
Int J Epidemiol. 2011 Apr;40(2):318-26
pubmed: 20154009
PLoS One. 2015 Apr 13;10(4):e0123345
pubmed: 25875851
Int J Tuberc Lung Dis. 2011 Jul;15(7):933-7
pubmed: 21682967
Int J Epidemiol. 2008 Oct;37(5):956-62
pubmed: 17998242
Public Health Action. 2014 Jun 21;4(2):113-5
pubmed: 26399210
Lancet. 2011 Jul 2;378(9785):57-72
pubmed: 21420161
Trop Med Int Health. 2016 Jan;21(1):101-107
pubmed: 26509352